Adicet Bio Advances Prula-Cel Toward SLE Data Readout
REDWOOD CITY, Calif., September 1, 2026 Adicet Bio announced completion of the last patient visit for the planned Phase...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
REDWOOD CITY, Calif., September 1, 2026 Adicet Bio announced completion of the last patient visit for the planned Phase...
FOSTER CITY, Calif. – August 27, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA)...
REDWOOD CITY, Calif. – August 27, 2026 Adicet Bio, Inc. announced that the U.S. Food and Drug Administration (FDA)...
